LumÃ-r HanuÅ¡

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10747941/publications.pdf

Version: 2024-02-01

24 papers	6,217 citations	393982 19 h-index	676716 22 g-index
26 all docs	26 docs citations	26 times ranked	4749 citing authors

#	Article	IF	Citations
1	Priority Considerations for Medicinal Cannabis-Related Research. Cannabis and Cannabinoid Research, 2019, 4, 139-157.	1.5	21
2	Cannabinoids and Cytochrome P450 Interactions. Current Drug Metabolism, 2016, 17, 206-226.	0.7	205
3	<scp>HU</scp>â€446 and <scp>HU</scp>â€465, Derivatives of the Nonâ€psychoactive Cannabinoid Cannabidiol, Decrease the Activation of Encephalitogenic T Cells. Chemical Biology and Drug Design, 2016, 87, 143-153.	1.5	24
4	Human Metabolites of Cannabidiol: A Review on Their Formation, Biological Activity, and Relevance in Therapy. Cannabis and Cannabinoid Research, 2016, 1, 90-101.	1.5	200
5	HU-444, a Novel, Potent Anti-Inflammatory, Nonpsychotropic Cannabinoid. Journal of Pharmacology and Experimental Therapeutics, 2015, 355, 66-75.	1.3	19
6	Nâ€Acyl amino acids and their impact on biological processes. BioFactors, 2014, 40, 381-388.	2.6	54
7	Novel Natural and Synthetic Ligands of the Endocannabinoid System. Current Medicinal Chemistry, 2010, 17, 1341-1359.	1.2	46
8	PLANT AND BRAIN CANNABINOIDS: THE CHEMISTRY OF MAJOR NEW PLAYERS IN PHYSIOLOGY. , 2007, , 49-75.		0
9	Peripheral, but not central effects of cannabidiol derivatives: Mediation by CB1 and unidentified receptors. Neuropharmacology, 2005, 48, 1117-1129.	2.0	34
10	The cannabinoid system: from the point of view of a chemist. , 2004, , 1-18.		2
11	(+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only. European Journal of Pharmacology, 2004, 506, 179-188.	1.7	42
12	The tornabeatins, four tetrahydro-2-furanone derivatives from the lichenized ascomycete Tornabea scutellifera (With.) J.R. Laundon. Phytochemistry, 2004, 65, 2605-2612.	1.4	16
13	Short-term fasting and prolonged semistarvation have opposite effects on 2-AG levels in mouse brain. Brain Research, 2003, 983, 144-151.	1.1	113
14	Chagosensine, a New Chlorinated Macrolide from the Red Sea SpongeLeucetta chagosensis. European Journal of Organic Chemistry, 2003, 2003, 4073-4079.	1.2	24
15	Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. Chemistry and Physics of Lipids, 2002, 121, 35-43.	1.5	204
16	Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. British Journal of Pharmacology, 2001, 134, 845-852.	2.7	945
17	An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature, 2001, 413, 527-531.	13.7	680
18	Characterization of the hypnotic properties of oleamide. NeuroReport, 1999, 10, 947-951.	0.6	85

#	Article	IF	Citations
19	Structural Requirements for Binding of Anandamide-Type Compounds to the Brain Cannabinoid Receptor. Journal of Medicinal Chemistry, 1997, 40, 659-667.	2.9	262
20	Cannabinol Derivatives:Â Binding to Cannabinoid Receptors and Inhibition of Adenylylcyclase. Journal of Medicinal Chemistry, 1997, 40, 3228-3233.	2.9	166
21	Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology, 1995, 50, 83-90.	2.0	2,561
22	Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides. European Journal of Pharmacology, 1995, 287, 145-152.	1.7	61
23	Search for endogenous ligands of the cannabinoid receptor. Biochemical Pharmacology, 1994, 48, 1537-1544.	2.0	133
24	Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. Journal of Medicinal Chemistry, 1993, 36, 3032-3034.	2.9	320